Wide Ranks

FHTX

Foghorn Therapeutics Inc.

7.79

Top Statistics
Market Cap 433 M Forward PE -5.74 Revenue Growth -55.30 %
Current Ratio 4.77 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.08 Enterprise / Revenue 8.02 Price To Sales Trailing12 Months 16.97
Profitability
Profit Margins 0.00 % Operating Margins -305.48 %
Balance Sheet
Total Cash 267 M Total Cash Per Share 4.81 Total Debt 39 M
Total Debt To Equity Current Ratio 4.77 Book Value Per Share -0.5090
All Measures
Short Ratio 737.00 % Message Board Id finmb_538076136 Shares Short Prior Month 1 M
City Cambridge Uuid abad74ee-88c2-3fa2-8f10-1f935407d35f Previous Close 7.52
First Trade Date Epoch Utc 1 B Book Value -0.5090 Beta 3.15
Total Debt 39 M Volume 66769 Fifty Two Week Low 2.70
Total Cash Per Share 4.81 Total Revenue 25 M Shares Short Previous Month Date 1 B
Target Median Price 17.00 Max Age 86400 Recommendation Mean 1.57
Sand P52 Week Change 0.3133 Operating Margins -305.48 % Target Mean Price 16.00
Net Income To Common -91223000 Short Percent Of Float 0.0234 Implied Shares Outstanding 55 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 110040
Average Volume10days 110040 Total Cash 267 M Next Fiscal Year End 1 B
Revenue Per Share 0.5130 Held Percent Insiders 0.1898 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 7.52
Target Low Price 9.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 8.26
Open 7.51 Free Cashflow -42247248 State MA
Dividend Yield 0.00 % Return On Assets -0.2045 Time Zone Short Name EST
Trailing Eps -1.85 Day Low 7.51 Address1 500 Technology Square
Shares Outstanding 55 M Price Hint 2 Target High Price 20.00
Website https://foghorntx.com 52 Week Change 0.8329 Average Volume 158981
Forward Eps -1.58 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 470.60 % Is_sp_500 False Regular Market Day High 7.83
Profit Margins 0.00 % Fifty Two Week High 10.25 Day High 7.83
Shares Short 983469 Regular Market Open 7.51 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 8.02 Revenue Growth -55.30 %
Shares Percent Shares Out 0.0177 Operating Cashflow -103428000 Currency USD
Time Zone Full Name America/New_York Market Cap 433 M Is_nasdaq_100 False
Zip 02139 Quote Type EQUITY Industry Biotechnology
Long Name Foghorn Therapeutics Inc. Regular Market Day Low 7.51 Held Percent Institutions 0.7211
Current Price 7.79 Address2 Suite 700 Enterprise To Ebitda -2.08
Financial Currency USD Current Ratio 4.77 Industry Disp Biotechnology
Number Of Analyst Opinions 6 Country United States Float Shares 26 M
Two Hundred Day Average 6.90 Enterprise Value 204 M Price To Sales Trailing12 Months 16.97
Forward PE -5.74 Regular Market Volume 66769 Ebitda -98527000
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.

The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome.

The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma.

It has a research collaboration and license agreement with Merck Sharp & Dohme Corp.

to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM.

Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.